Newsroom

Sorted by: Latest

-

Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3 Bodycote plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...
-

NATIXIS UK Regulatory Announcement: Form 8.3 Gamma communications plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

Tesla Third Quarter 2026 Production, Deliveries & Deployments

AUSTIN, Texas--(BUSINESS WIRE)--In the third quarter, we produced over 464,000 vehicles, delivered over 486,000 vehicles and deployed 13.7 GWh of energy storage products. Thank you to all of our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q3 2026   Production Deliveries Subject to operating lease accounting Model 3/Y 457,387 478,237 1 % Other Models 7,004 8,295 4 % Total 464,391 486,532 1 % Tesla will post its financial results for the third...
-

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki...
-

Singleton Associates and Blue Cross and Blue Shield of Texas Sign Long-Term Agreement to Protect In-Network Access to Radiology Care in Texas

NASHVILLE, Tenn.--(BUSINESS WIRE)--Singleton Associates, P.A. (Singleton Associates), a Radiology Partners-affiliated practice, and Blue Cross and Blue Shield of Texas (BCBSTX) have reached a new multi-year agreement, effective November 1, 2026. This long-term agreement represents a significant achievement for patients, providers, and healthcare organizations across Texas, reflecting both organizations’ commitment to network stability, continuity of care and uninterrupted access to high-quality...
-

Aulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual Meeting

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. One presentation will focus on promising Phase 2 results for imneskibart with avelumab in checkpoint inhibi...
-

NATIXIS UK Regulatory Announcement: Form 8.3 Beazley plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3 DCC plc

LONDON--(BUSINESS WIRE)--  Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, t...
-

Meet the Ninja PREPi Precision-Powered Prep - Store System: Prep, Serve, Store & Go - All with One Bowl.

NEEDHAM, Mass.--(BUSINESS WIRE)--SharkNinja, Inc. (NYSE: SN), a leading global product design and technology company, today announced the launch of the Ninja PREPi™ Precision-Powered Prep + Store System. The compact system tackles time-consuming dicing, chopping, slicing, shredding, puréeing and even crinkling — all in a single bowl that goes from prep to table to fridge to out the door in no time. Whether you’re tired of dropping $18 on a salad, or fresh out of time to make dinner after a long...
-

Blackfuel se dévoile avec plus de 250 millions de dollars de revenus contractualisés pour construire un AI Token Grid mondial

PARIS--(BUSINESS WIRE)--Blackfuel se dévoile aujourd’hui avec plus de 250 millions de dollars de revenus contractualisés dans le cadre d’accords clients pluriannuels, annonçant son ambition de construire un AI Token Grid mondial, un réseau mondial de capacités d’inférence. Pionnière de l’AI Token Grid, Blackfuel met en place un réseau de clusters dédiés chacun à une architecture d’accélérateurs et reliés par une couche logicielle et commerciale commune. Ce réseau est conçu pour transformer la p...